Neosaxitoxin is a pyrrolopurine that is saxitoxin carrying a hydroxy substituent on the nitrogen atom at position 5.
Definition
US FDA substance register · UNII 6YRL8BWD9H · registered name NEOSAXITOXIN · single chemical substance
Neosaxitoxin is a pyrrolopurine that is saxitoxin carrying a hydroxy substituent on the nitrogen atom at position 5. It is a sodium channel blocker that is undergoing clinical trials as a prolonged-duration local anesthetic. It has a role as a toxin, a local anaesthetic, a voltage-gated sodium channel blocker, a neurotoxin, an anti-inflammatory agent, a marine metabolite and a cyanotoxin. It is a pyrrolopurine, a paralytic shellfish toxin, an alkaloid, a carbamate ester, a member of guanidines, a member of hydroxylamines and a ketone hydrate. It is functionally related to a saxitoxin.
Source: PubChem
Neosaxitoxin is a neurotoxin isolated from algae cyanobacteria cells. It conforms to the formula
Cosmetic roles
More data — names, identifiers, properties, test records, literature
Names & identifiers
- CAS No.chemical registry number
- 64296-20-4
- EC No.EU chemical inventory number
- 809-831-0
- DTXSIDUS EPA chemical ID
- DTXSID70880098
- DTXCIDUS EPA compound ID
- DTXCID401529215
- IUPAC
- [(3aS,4R,10aS)-2-Amino-5,10,10-trihydroxy-6-imino-3a,4,5,6,9,10-hexahydro-1H,8H-pyrrolo[1,2-c]purin-4-yl]methyl carbamate
- Molecular formula
- C10H17N7O5
- Molecular weight
- 315.29 g/mol
What products actually use it for
What the 5 products reported to the US EPA with this ingredient use it for. Products outside cosmetics are included, so the top few rows are its main uses.
- Astringent (EPA)1
- Antioxidant1
- Antiperspirant (EPA)1
- Dye1
- Humectant1
Source: US EPA CompTox dashboard
Related literature
- Site-1 Sodium Channel Blockers as Local Anesthetics: Will Neosaxitoxin Supplant the Need for Continuous Nerve Blocks? · 2015
- Neosaxitoxin, a Long-Lasting Local Anesthetic and its Potential Clinical Applications in Horses · 2023
- Faculty Opinions recommendation of A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. · 2017
- A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia · 2015
- Neosaxitoxin as a Local Anesthetic: Preliminary Observations from a First Human Trial · 2007